In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $1.44.
According to TipRanks, Trucchio is an analyst with an average return of -18.5% and a 30.63% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Altimmune, and Milestone Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Invivyd with a $3.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
IVVD market cap is currently $157.2M and has a P/E ratio of -0.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
Read More on IVVD:
- Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
- Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
- Invivyd initiated with a Buy at H.C. Wainwright
- Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
- Invivyd announces FDA has cleared IND application for VYD222
